REGENXBIO
Clinical-stage biotechnology company developing AAV-based gene therapies for retinal, neuromuscular and neurodegenerative diseases. Operates an in‑house cGMP manufacturing facility and a proprietary AAV vector platform; advances internal product candidates through preclinical studies and multi‑phase clinical trials and selectively licenses vector technology to partners.
Industries
Nr. of Employees
large (251-1000)
Patents
Treatment of dystrophinopathies with microdystrophin gene therapy constructs
US-12766200-B2
View DetailsSystems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
US-12761144-B2
View Details
Treatment of dystrophinopathies with microdystrophin gene therapy constructs
US-12766200-B2
View DetailsSystems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
US-12761144-B2
View DetailsProducts
RGX-314 (surabgene lomparvovec)
Investigational AAV-based ocular gene therapy designed to inhibit VEGF activity for wet age-related macular degeneration and diabetic retinopathy; evaluated via subretinal and suprachoroidal delivery routes.
RGX-202
Investigational AAV8-based microdystrophin gene therapy for Duchenne muscular dystrophy designed to deliver a novel microdystrophin that includes C‑terminal functional elements and a muscle-specific promoter to skeletal and cardiac muscle.
RGX-121
Investigational AAV9-based gene therapy designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system for treatment of neuronopathic mucopolysaccharidosis type II (MPS II, Hunter syndrome).
RGX-314 (surabgene lomparvovec)
Investigational AAV-based ocular gene therapy designed to inhibit VEGF activity for wet age-related macular degeneration and diabetic retinopathy; evaluated via subretinal and suprachoroidal delivery routes.
RGX-202
Investigational AAV8-based microdystrophin gene therapy for Duchenne muscular dystrophy designed to deliver a novel microdystrophin that includes C‑terminal functional elements and a muscle-specific promoter to skeletal and cardiac muscle.
RGX-121
Investigational AAV9-based gene therapy designed to deliver the iduronate-2-sulfatase (IDS) gene to the central nervous system for treatment of neuronopathic mucopolysaccharidosis type II (MPS II, Hunter syndrome).
Services
Selective licensing of proprietary AAV vector technology to external biotechnology and pharmaceutical partners.
Selective licensing of proprietary AAV vector technology to external biotechnology and pharmaceutical partners.
Expertise Areas
- AAV vector engineering and platform development
- Gene therapy construct design (transgene and promoter optimization)
- Preclinical model development and translational pharmacology
- Clinical trial design and execution for gene therapies
Key Technologies
- Adeno-associated virus (AAV) vectors
- Suspension-based scalable AAV manufacturing
- Producer cell lines and custom plasmids for AAV production
- qPCR for vector copy number (VCN)
News & Updates
Presentation describing multi-year durability data for suprachoroidal delivery of surabgene lomparvovec in diabetic retinopathy showing >2-step DRSS improvement in a majority of participants at 3 years with no vision-threatening events reported in the release.
Conference presentation on 3-year results following suprachoroidal delivery of surabgene lomparvovec for non-proliferative diabetic retinopathy.
Interim clinical dataset and presentations describing biomarker, safety and functional outcomes from RGX-202 AFFINITY DUCHENNE Phase I/II program.
Operates a cGMP Manufacturing Innovation Center designed for AAV vector production at scales up to 2,000 L to support clinical and commercial supply.
RGX-202 has received Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation from the U.S. FDA.
Public materials list a planned or completed BLA filing activity for a CNS program (RGX-121 referenced with BLA filing in 2024 in pipeline table).
Presentation describing multi-year durability data for suprachoroidal delivery of surabgene lomparvovec in diabetic retinopathy showing >2-step DRSS improvement in a majority of participants at 3 years with no vision-threatening events reported in the release.
Conference presentation on 3-year results following suprachoroidal delivery of surabgene lomparvovec for non-proliferative diabetic retinopathy.
Interim clinical dataset and presentations describing biomarker, safety and functional outcomes from RGX-202 AFFINITY DUCHENNE Phase I/II program.
Operates a cGMP Manufacturing Innovation Center designed for AAV vector production at scales up to 2,000 L to support clinical and commercial supply.
RGX-202 has received Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation from the U.S. FDA.
Public materials list a planned or completed BLA filing activity for a CNS program (RGX-121 referenced with BLA filing in 2024 in pipeline table).